SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS said its Phase 3 REGAL AML trial reached the 80-event threshold, triggering final analysis ahead of topline results; the milestone does not reveal whether GPS is effective. Traders debate the sharp selloff as profit-taking and caution ahead of a binary readout versus alleged short-driven pressure, while bullish traders buy the dip.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs post-earnings selloff and repeated 52-week lows are driving discussion, with traders focused on weaker forward guidance, a reduced advertising outlook, and concerns about slowing viewing and growth amid competition. Reactions are sharply divided between holders calling the decline an overreaction and buyers averaging down, and bears questioning management, content, and the streaming businesss prospects.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

A Trian-led consortiums proposal to take Wendys private drove the rally. Traders are divided over whether the offer undervalues the company, with many expecting the board to reject or counter and some speculating about a competing bid or short squeeze; the proposal is not a completed deal.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

UBER is drawing attention for persistent selling that has pushed shares to fresh 52-week lows, with traders frustrated by weak price action and looking ahead to earnings for a possible catalyst. The debate centers on whether autonomous-vehicle competition threatens Ubers business, while some investors view the selloff as a buying opportunity given the companys fundamentals.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynixs record quarterly results, strong AI-driven memory demand, and plans for substantial dividends and buybacks are driving attention, with traders also citing tight memory supply and long-term customer commitments. The reaction is largely bullish, though some question why the shares have not risen further and warn that the strong results may reflect a cyclical peak or invite a sell-the-news pullback.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphases quarterly results missed expectations and its weaker outlook reflected soft residential solar demand amid high interest rates and the loss of a federal tax credit, driving a sharp selloff. Traders are split between expecting further downside and buying the dip, with some pointing to the AI data-center transformer opportunity as a longer-term prospect while noting that it remains years away.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernovas quarterly beat and raised outlook are being overshadowed by its planned Trench Group acquisition, with traders debating whether the deals price and financing justify the selloff. Some view the decline as a sell-the-news overreaction and point to strong power-equipment demand and backlog, while others question the acquisitions capital-allocation impact.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertivs quarterly results beat expectations, organic orders more than doubled, and the company raised its full-year outlook, reinforcing its exposure to AI data-center power and cooling demand. Traders largely welcomed the results as evidence the buildout remains strong, while some cautioned against chasing the sharp rally and pointed to valuation and profit-taking risks.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientifics earnings report paired a modest beat with a weaker outlook, including an expected fourth-quarter sales decline, renewing concern about the financial impact of its cyberattack-related disruptions. Traders criticized management and debated whether the cyber incident explains the slowdown or masks deeper business issues, while some viewed the selloff as a buying opportunity.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generacs quarterly results are driving discussion: traders point to record sales and a larger data-center backlog, while some are disappointed that full-year guidance was maintained and question the margins on commercial growth. The reaction is mixed, with optimism about data-center demand offset by concerns that the outlook did not improve further.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million.
Aethlon Medical (NASDAQ:AEMD) shares moved upwards byread more...

Biotech Bombshells and AI Power Plays: The Stocks Suddenly Turning Heads

Today’s market action is being driven by hard catalysts. Quoin Pharmaceuticals (NASDAQ:QNRX) has fresh interim clinical data; NeOnc Technologies Holdings (NASDAQ:NTHI) has moved its NEO100 story toward an FDA registration discussion; FingerMotion (NASDAQ:FNGR) is attempting a major strategic pivot toward AI infrastructure; and Solstice Advanced Materials (NASDAQ: SOLS) has replaced a transformative merger with a $500 million buyback and an independent-growth narrative. Meanwhile, Gap (NYSE: GAP) is demonstrating that a mature consumer company can still generate sharp divergence between individual brands.

Quoin Pharmaceuticals Stock Surges Friday: What's Happening?

Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial results and a major institutional financing.read more...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million.
Aethlon Medical (NASDAQ:AEMD) stock moved upwards byread more...

Quoin’s Netherton Data Turns Heads and Could Make QRX003 Breakout Catalyst

Quoin Pharmaceuticals (NASDAQ:QNRX) delivered the kind of interim clinical signal that can abruptly change the conversation around a small-cap biotech: its investigational QRX003 lotion produced statistically significant improvements in key measures of Netherton Syndrome in the first six patients to complete 12 weeks of treatment. The company says four of six participants, or 66.7%, achieved at least a one-grade improvement on the Investigator Global Assessment, producing a p=0.0087 result that cleared the study’s pre-specified interim alpha of 0.0215.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million.
Mobile-health Network (NASDAQ:MNDR)read more...

Quoin Pharmaceuticals Garners Buzz After FDA’s Comments On Netherton Syndrome Lead Drug

Equity

The U.S. Food and Drug Administration indicated that a single Phase 3 trial of QRX003 could be enough to support approval in the U.S.

Quoin Pharmaceuticals Gains FDA Alignment, Eyes Streamlined Path to First Netherton Syndrome Treatment

Quoin Pharmaceuticals (NASDAQ:QNRX) reported a key regulatory milestone following a constructive Type C meeting with the U.S. Food and Drug Administration (FDA), potentially accelerating the development path for its lead candidate, QRX003, in the treatment of Netherton Syndrome, a rare and underserved genetic skin disorder.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Quoin Pharmaceuticals Ltd - ADR

Registration filing

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>The FDA indicated openness to alternative trial designs such as not using a placebo group for the Phase 3 trial.</li><li>Quoin remains on track to complete patient enrollment for the next phase, it added.</li><li>Last week, the FDA granted Fast Track designation to the company’s QRX003.</li></ul>Shares of Quoin Pharmaceuticals (QNRX) gave up most of its early gains to trade 1 % higher on Wednesday, after the company said it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) for its lead drug QRX003 to treat Netherton Syndrome, a genetic disorder that results in severe allergies.The FDA indicated that a single Phase 3 trial may be sufficient to support U.S. approval, rather than the usual two studies. The agency also showed openness to alternative trial designs like randomized withdrawal or delayed-start studies, instead of a traditional placebo-controlled Phase 3 trial.<h2 class="st-heading-2">Phase 3 Trial Remains On Track</h2>Following the Type C meeting, Quoin plans to move ahead with its Phase 3 program and remains on track to complete patient enrollment. The company said it could file for approval as early as 2027.“With our established network of U.S. and EU clinical trial sites, we are confident that we will be in a position to initiate our pivotal Phase 3 program and fully complete recruitment this year,” said CEO Michael Myers.This comes just a week after the FDA granted Fast Track designation to QRX003. The drug is currently being tested in two late-stage trials to evaluate safety and effectiveness. QRX003 has already received Orphan Drug status in both the U.S. and Europe.Quoin also&nbsp;submitted an Orphan Drug Designation (ODD) application for&nbsp;QRX003 in Japan and a&nbsp;Breakthrough Medicine Designation with the Saudi Food and Drug Authority earlier this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/QNRX">QNRX</a> flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said given the company’s potential, the stock has been “beaten down”<stembedurl>https://stocktwits.com/revuelto/message/648496398</stembedurl>The stock has been under heavy selling pressure this year, slumping around 45%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

50bps hike

25bps hike

No change

Rate cut

The Federal Reserve announces its rate decision Wednesday, October 28 at 2:00 PM ET, followed by Chair Kevin Warsh’s press conference at 2:30 PM, after raising rates by a quarter point to 3.75%-4.00% in September, its first hike since 2023. What do you think the Fed decides on Wednesday? Vote and explain your reasoning in the comments.

Current Price	$3.91
Prev Close	$4.05
Open	$4.07
Dividend Yield	0.00%
50-Day Moving Average	$5.47
Beta	0.63
Avg. Volume	100,575.84
PE Ratio	-0.27

52-Week High	$23.50
52-Week Low	$3.25
Market Capitalization	$8.13M
EPS (Annual)	-$10.63
Price to Book	2.07
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

QNRX Fundamentals